Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul 22;6(1):281.
doi: 10.1038/s41392-021-00707-z.

Epigenetic checkpoint blockade: new booster for immunotherapy

Ziqiao Wang  1 , Bingjing Wang  1 , Xuetao Cao  2   3
Affiliations
Comment

Epigenetic checkpoint blockade: new booster for immunotherapy

Ziqiao Wang et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

X.C. is one of the Associate Editors of Signal Transduction and Targeted Therapy, but he has not been involved in the process of the manuscript handling. The other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The schematic of SETDB1 repression in promoting the cytotoxic T-cell responses against tumor. Inhibition of SETDB1 induces extensive TEs expression and segmental duplications that not only activate immune-related genes but also encode MHC-I peptides as neoantigens, leading to the enhanced immunogenicity and killing susceptibility of tumor cells. Me methylation, Ac acetylation, TEs transposable elements, TFs transcriptional factors, ORF open reading frame, ICB immune checkpoint blockade
See this image and copyright information in PMC

Comment on

  • Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity.
    Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, Dele-Oni D, Du PP, Halawi AG, Ishizuka JJ, Kim SY, Klaeger S, Knudsen NH, Miller BC, Nguyen TH, Olander KE, Papanastasiou M, Rachimi S, Robitschek EJ, Schneider EM, Yeary MD, Zimmer MD, Jaffe JD, Carr SA, Doench JG, Haining WN, Yates KB, Manguso RT, Bernstein BE. Griffin GK, et al. Nature. 2021 Jul;595(7866):309-314. doi: 10.1038/s41586-021-03520-4. Epub 2021 May 5. Nature. 2021. PMID: 33953401 Free PMC article.

References

    1. Griffin GK, et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021;595:309–314. doi: 10.1038/s41586-021-03520-4. - DOI - PMC - PubMed
    1. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer. 2011;11:726–734. doi: 10.1038/nrc3130. - DOI - PMC - PubMed
    1. Jiang H, et al. DNA methylation markers in the diagnosis and prognosis of common leukemias. Sig. Transduct. Target. Ther. 2020;5:3. doi: 10.1038/s41392-019-0090-5. - DOI - PMC - PubMed
    1. Zhang Q, Cao X. Epigenetic remodeling in innate immunity and inflammation. Annu. Rev. Immunol. 2021;39:279–311. doi: 10.1146/annurev-immunol-093019-123619. - DOI - PubMed
    1. Ryu H, et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington’s disease. Proc. Natl Acad. Sci. USA. 2006;103:19176–19181. doi: 10.1073/pnas.0606373103. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances